The role of the direct oral anticoagulants (DOACs) in practice has been given extensive
consideration recently, albeit largely from the clinician's perspective. However, the …

Efforts to reduce stroke in atrial fibrillation (AF) have focused on increasing physician
adherence to oral anticoagulant (OAC) guidelines, but high early vitamin K antagonist (VKA) …

Dabigatran is approved for stroke risk reduction in patients with nonvalvular atrial fibrillation
(NVAF). Data from diverse clinical practice settings will help establish whether the risk …

Introduction Patients' lack of knowledge is a key barrier to therapy adherence. We aimed to
gather insights into atrial fibrillation (AF) patients' education needs from patient and clinician …

For patients taking vitamin K antagonist (VKA) anticoagulants, poor adherence to the drug
regimen is associated with a lower percent time in therapeutic range and also with an …

Objectives: To identify factors associated with all-cause discontinuation (patient
discontinued on their own or physician discontinuation) of oral anticoagulants (OACs) …

Methods Patients with a claim for dabigatran and who were continuously enrolled in
pharmacy benefits for 180 days prior to and 180 days following the initiation of dabigatran …

Methods In a prospective observational registry (COmparison study of Drugs for symptom
control and complication prEvention of Atrial Fibrillation [CODE-AF] registry), 7,013 patients …

Background Dabigatran, an oral direct thrombin inhibitor, possesses several advantages
over warfarin that can in principle simplify the management of stroke prevention in atrial …

Atrial fibrillation (AF) is a common cardiovascular disease for which newer oral
anticoagulants are available. The main objective of this study was to evaluate the …